CMPX · Insider Trading
Compass Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by CMPX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Neil Lerner | Chief Accounting Officer | Buy | +20,000 | +$18.40K |
| 2026-09-25 | Neil Lerner | Chief Accounting Officer | Buy | +2,500 | +$2.85K |
| 2026-04-29 | Neil Lerner | Chief Accounting Officer | A | +15,000 | +$28.35K |
| 2026-04-29 | Jonathan Anderman | General Counsel | A | +25,000 | +$47.25K |
| 2026-02-10 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | F | −36,687 | −$239.20K |
| 2026-01-12 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | F | −46,777 | −$250.26K |
| 2026-01-05 | Cynthia Sirard | Chief Medical Officer | A | +1,000,000 deriv. | — |
| 2026-01-05 | Carl L Gordon | Director | A | +90,000 deriv. | — |
| 2026-01-05 | Richard S Lindahl | Director | A | +90,000 deriv. | — |
| 2026-01-05 | Jonathan Anderman | General Counsel | A | +150,000 | +$775.50K |
| 2026-01-05 | Mary Ann Gray | Director | A | +90,000 deriv. | — |
| 2026-01-05 | Arjun Prasad | Chief Commercial Officer | A | +1,000,000 deriv. | — |
| 2026-01-05 | Neil Lerner | Chief Accounting Officer | A | +62,500 | +$323.12K |
| 2026-01-05 | Barry Shin | CFO | A | +125,000 | +$646.25K |
| 2026-01-05 | Thomas J. Schuetz | CEO | A | +250,000 | +$1.29M |
| 2026-01-05 | James P Boylan | Director | A | +90,000 deriv. | — |
| 2026-01-05 | Ellen Chiniara | Director | A | +90,000 deriv. | — |
| 2026-01-05 | Philip Ferneau | Director | A | +90,000 deriv. | — |
| 2025-11-18 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | F | −44,025 | −$212.64K |
| 2025-05-27 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | Buy | +10,000 | +$21.10K |
| 2025-04-11 | OrbiMed Capital GP VI LLC | Director | Sell | −10,714,284 | −$17.04M |
| 2025-04-11 | Carl L Gordon | Director | Sell | −3,571,428 | −$5.68M |
| 2025-04-08 | Neil Lerner | CHIEF ACCOUNTING OFFICER | Buy | +20,000 | +$28.40K |
| 2025-04-08 | Jonathan Anderman | Gen Counsel & Corporate Sec | Buy | +20,000 | +$30.80K |
| 2025-02-13 | James P Boylan | Director | A | +40,000 deriv. | — |
| 2025-02-13 | Jonathan Anderman | Sr VP, Gen Counsel & Corp Sec | A | +280,000 deriv. | — |
| 2025-02-13 | Barry Shin | CFO | A | +250,000 deriv. | — |
| 2025-02-13 | Neil Lerner | SVP, CAO | A | +200,000 deriv. | — |
| 2025-02-13 | Mary Ann Gray | Director | A | +40,000 deriv. | — |
| 2025-02-13 | Philip Ferneau | Director | A | +40,000 deriv. | — |
| 2025-02-13 | Richard S Lindahl | Director | A | +40,000 deriv. | — |
| 2025-02-13 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | A | +1,500,000 deriv. | — |
| 2025-02-13 | Carl L Gordon | Director | A | +40,000 deriv. | — |
| 2025-02-13 | Ellen Chiniara | Director | A | +40,000 deriv. | — |
| 2025-02-11 | Thomas J. Schuetz | CEO | F | −41,687 | −$145.90K |
| 2025-01-13 | Thomas J. Schuetz | CEO | F | −58,054 | −$107.98K |
| 2024-12-10 | Barry Shin | CFO | A | +400,000 | +$660.00K |
| 2024-08-14 | Jonathan Anderman | Sr VP, Gen Counsel & Corp Sec | A | +300,000 deriv. | — |
| 2024-03-11 | James P Boylan | Director | A | +40,000 deriv. | — |
| 2024-02-14 | Mary Ann Gray | Director | A | +40,000 deriv. | — |
| 2024-02-14 | Ellen Chiniara | Director | A | +40,000 deriv. | — |
| 2024-02-14 | Richard S Lindahl | Director | A | +40,000 deriv. | — |
| 2024-02-14 | Philip Ferneau | Director | A | +40,000 deriv. | — |
| 2024-02-14 | Carl L Gordon | Director | A | +40,000 deriv. | — |
| 2024-02-09 | Vered Bisker-Leib | CHIEF EXECUTIVE OFFICER | F | −49,198 | −$71.34K |
| 2024-02-09 | Thomas J. Schuetz | PRESIDENT | F | −44,782 | −$64.93K |
| 2024-01-10 | Vered Bisker-Leib | Chief Executive Officer | A | +1,753,125 | +$3.38M |
| 2024-01-10 | Thomas J. Schuetz | President of R&D | A | +637,500 | +$1.23M |
| 2023-11-21 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | F | −44,025 | −$66.04K |
| 2023-11-21 | Vered Bisker-Leib | Chief Operating Officer | F | −64,415 | −$96.62K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Carl L Gordon | Director | 15,219,994 | $11.93M |
| OrbiMed Capital GP VI LLC | Director | 15,219,994 | $11.93M |
| Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | 6,603,336 | $5.18M |
| Barry Shin | CFO | 525,000 | $411.55K |
| Neil Lerner | Chief Accounting Officer | 420,000 | $329.24K |
| Jonathan Anderman | General Counsel | 196,000 | $153.64K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CMPX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.